Pfizer Plans to Request FDA Authorization for Covid Booster

Pfizer Inc. and BioNTech announced plans to request U.S. emergency authorization for a third booster dose of its vaccine. The release states, “Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks.” Watch more below as Bloomberg’s Robert Langreth breaks down the implications of the announcement.

Host: And Robert, Heidi was just saying earlier that here in the US, everything is back to normal. We’re going to get boosters even before they get their first dose. What do we know so far?

Langreth: Yes,  I talked to the head of research today, and they’re as you said, they’re going to apply for a third dose booster in the emergency authorization in the US in a month. And that’s based on a small study of 10 to 20 people that shows giving a third dose that some of the existing vaccine, six to eight months later, that can bolster and neutralize antibody levels by 5 to 10-fold. And they think that’s going to be enough to help provide some further protection against, say, the delta variant. In Israel, there’s been some mild breakthrough cases there. And it may just be because antibodies are waning a little bit after you’ve been vaccinated for six months.

Host: Robert, and that’s exactly why we’re seeing, I guess, more infections in young people who are largely unvaccinated at this point. What is the data showing across the vaccine options as to how effective they are against delta?

Langreth: Yeah, so basically the way to think about it is that the vaccines, especially the more effective vaccines, they’re still holding against delta and they still give you strong protection against severe disease and hospitalization against delta. Now, there was this recent report out of Israel that indicated that while the protection against severe disease was still strong, that protection with the vaccine was only 64% against symptomatic disease recently. And Pfizer’s thinking is that basically the antibodies have faded a little bit because Israel is one of the first companies to really get going in the vaccination campaign. So some of the first people to get the antibodies might have faded a little bit, and that might allow a very transmissible variant to kind of penetrate through a little bit and cause some initial mild infection before kind of the more longer lasting components of the immune system response kick in.

Host: So what’s the outlook for places like Japan, where you have thousands, hundreds of athletes coming in from abroad and they’re not fully immunized or the vaccination rollout has been pretty slow still?

Langreth: Well, I mean, this virus is highly transmissible. It’s become more transmissible among people that aren’t fully vaccinated or aren’t vaccinated at all. It’s still a definite danger. And people still definitely need to make take strong precautions because it’s gotten more transmissible over time, not less.

*Bloomberg contributed to this content

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

student success
The AI-Powered Edge in Education: How LearningClues Is Enabling Student Success with Co-founder and CEO Dr. Perry Samson
June 30, 2025

As AI continues to reshape education, institutions face a growing challenge in ensuring students succeed without compromising engagement or integrity. Today’s college students are often juggling jobs, family, and coursework, leading to limited study time and increased dropout risk. According to the National Center for Education Statistics, 40% of full-time undergraduates and 74% of…

Read More
AI Strategist
Why Enterprises Need an AI Strategist and Why It Should Be a Marketer
June 30, 2025

In this episode of The Marketing AI SparkCast, Aby Varma, founder of Spark Novus, a leading consultancy that partners with marketing leaders to adopt and scale AI responsibly and strategically, talks with Nicola Smith, Senior AI Programs Advisor at Southwest Airlines. They explore how enterprises can move beyond tool experimentation to embed AI into…

Read More
first 90 days
HealthSearch Partners’ Neill Marshall and Kurt Mosley Urge New CEOs to Listen First, Diagnose Early, and Lead with Purpose in the First 90 Days
June 30, 2025

CEO turnover across U.S. hospitals is accelerating. Hospitals and health systems announced 146 CEO changes in 2023—a 42 percent increase over the 103 exits recorded in 2022, according to a Challenger, Gray & Christmas report. As more leaders transition into new roles, the importance of making a good first impression has intensified. The early…

Read More
tech talent
The DisruptED World of Tech Talent with TEKsystems: Future-Proofing the Workforce Through Inclusive Hiring and Non-Traditional Education
June 27, 2025

In a workforce reshaped by automation, accelerated AI adoption, and persistent labor shortages, the demand for skilled tech talent has never been more urgent—or more difficult to meet. The traditional pipelines, namely college degrees and four-year institutions, are no longer producing enough candidates to meet the explosive growth in tech roles. With tech jobs…

Read More